MyTACTIC: Activity of targeted therapy in patients (pts) with advanced solid tumors harboring specific biomarkers

被引：0
|
作者：
Schwartzberg, Lee S.
Spigel, David R.
VanderWalde, Ari
Zuniga, Richard Michael
Hong, Jason
Szado, Tania
Yoo, Bongin
Passler, Luke
Wang, Yong
Darbonne, Walter C.
Daniel, Davey
机构：
[1] Renown Hlth Pennington Canc Inst, Reno, NV USA
[2] Sarah Cannon Res Inst, Nashville, TN USA
[3] West Canc Ctr & Res Inst, Clin Res, Germantown, TN USA
[4] OneOncol Inc, Nashville, TN USA
[5] Genentech Inc, US Med Affairs Oncol, South San Francisco, CA USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2024年 / 42卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
3100
引用
收藏
页数：1
相关论文
共 50 条
  • [21] Safety and pharmacokinetics (PK) of tusamitamab ravtansine (tusa) in Japanese patients (pts) with advanced solid tumors
    Yamazaki, Kentaro
    Yoshino, Takayuki
    Honda, Kazunori
    Kuboki, Yasutoshi
    Kawakami, Takeshi
    Mitani, Seiichiro
    Nakamura, Yoshiaki
    Taniguchi, Hiroya
    Bando, Hideaki
    Tanaka, Tomoyuki
    Tada, Keisuke
    Fagniez, Nathalie
    Muro, Kei
    ANNALS OF ONCOLOGY, 2022, 33 : S506 - S506
  • [22] Phase I study of WNT974+spartalizumab in patients (pts) with advanced solid tumors
    Janku, Filip
    de Vos, Filip
    de Miguel, Maria
    Forde, Patrick
    Ribas, Antoni
    Nagasaka, Misako
    Argiles, Guillem
    Arance, Ana Maria
    Calvo, Aitano
    Giannakis, Marios
    Melendez, Maritza
    Gong, Jiachang
    Szpakowski, Sebastian
    Kan, Rebecca
    Moody, Susan E.
    De Jonge, Maja
    CANCER RESEARCH, 2020, 80 (16)
  • [23] Lurbinectedin (PM01183) in combination with paclitaxel (P) in patients (pts) with advanced solid tumors
    Garralda, E.
    Stathis, A.
    Drilon, A.
    Boni, V.
    Hyman, D.
    Calvo, E.
    Griguolo, G.
    Makker, V.
    Doger, B.
    Canziani, L.
    Varghese, A. M.
    Jimenez, E.
    Luque, J.
    Soto-Matos, A.
    Szyldergemajn, S.
    Sessa, C.
    EUROPEAN JOURNAL OF CANCER, 2015, 51 : S66 - S66
  • [24] Safety and tolerability of the olaparib tablet formulation in Japanese patients (pts) with advanced solid tumors (ASTs)
    Takahashi, Yasuo
    Fujikawa, Koshi
    Sagawa, Tamotsu
    Yonemori, Kan
    Tamura, Kenji
    Kodaira, Makoto
    Esaki, Taito
    Shirakawa, Tsuyoshi
    Hirai, Fumihiko
    Yokoi, Yuki
    Kawata, Toshio
    Hatano, Ben
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [25] Genomic Medicine and Targeted Therapy for Solid Tumors
    Stevens, Emily A.
    Rodriguez, Cristina P.
    JOURNAL OF SURGICAL ONCOLOGY, 2015, 111 (01) : 38 - 42
  • [26] Targeted therapy for solid tumors: Current status
    Zureikat, Amer H.
    McKee, Mark D.
    SURGICAL ONCOLOGY CLINICS OF NORTH AMERICA, 2008, 17 (02) : 279 - +
  • [27] Targeted radionuclide therapy for solid tumors: An overview
    DeNardo, Sally J.
    DeNardo, Gerald L.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2006, 66 (02): : S89 - S95
  • [28] A genomic signature of chemotherapeutic multidrug resistance provides a rational approach to identify patients for targeted therapy in advanced solid tumors
    Anguiano, A., Jr.
    Mori, S.
    Chang, J.
    Vlahovic, V.
    Kelley, M. J.
    Ginsburg, G.
    Dressman, H.
    Nevins, J. R.
    Potti, A.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [29] Effect of Erdafitinib on the Pharmacokinetics of Midazolam and Metformin in Patients With Advanced Solid Tumors Harboring FGFR Gene Alterations
    Zhu, Wei
    Baig, Mahadi
    Naini, Vahid
    De Meulder, Marc
    Akapame, Sydney
    De Zwart, Loeckie
    Haddish-Berhane, Nahor
    Triantos, Spyros
    CLINICAL PHARMACOLOGY IN DRUG DEVELOPMENT, 2024, 13 (10): : 1164 - 1176
  • [30] A phase II study of futibatinib (TAS-120) in patients (pts) with advanced (adv) solid tumors harboring fibroblast growth factor receptor (FGFR) genomic aberrations
    Hollebecque, Antoine
    Doi, Toshihiko
    Saavedra, Omar
    Takahashi, Osamu
    He, Helen
    Benhadji, Karim A.
    Shitara, Kohei
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (04)
12345